Mirus Bio LLC: Faster Biotherapeutic Protein Production With the New TransIT-PRO(TM) Transfection Kit

Published: Aug 19, 2010

MADISON, Wis., Aug. 18 /PRNewswire/ -- Mirus Bio now offers a new transfection kit ideal for biotherapeutic protein production in large pharma and biotech settings. Mirus Bio's new TransIT-PRO Kit will decrease time to produce usable protein by maximizing target protein yields through transient transfection. TransIT-PRO Kit uses animal origin free components designed for high and reproducible protein yield in suspension CHO and 293 derived cells. Since it is compatible with varied media formulations, the same media can be used for both transient and stable expression. TransIT-PRO outperforms linear PEI in protein yield and reproducibility while providing a cost-effective alternative to FreeStyle MAX.

(Logo: http://photos.prnewswire.com/prnh/20100818/CG52502LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100818/CG52502LOGO)

With TransIT-PRO you will:

  • Achieve high protein yield in suspension CHO and 293 cells
  • Experience compatibility with multiple CHO media formulations
  • Obtain reproducible protein expression with minimal optimization

Visit www.mirusbio.com for all your transfection needs including access to the citations database, data, protocols, technical support, inquiries about bulk pricing or to place an order.

The Transfection Experts

More than 15 years of gene delivery expertise.

Mirus pioneered scientific breakthroughs in non-viral gene delivery. These advancements established our products as industry leading transfection reagents. At Mirus, we continue to grow our expertise in nucleic acid delivery research and products to better serve you.


Back to news